Document is current

Article History

Received: 28 November 2023

Revised: 17 June 2024

Accepted: 27 June 2024

First Online: 9 July 2024

Competing interests

: SK: Received consultancy, honoraria, Board of Directors or advisory board/committee membership, travel/accommodation support and/or research funding from AbbVie, Alexion, AOP Orphan Pharmaceuticals, AOP Pharma, Ariad, Bayer, Bedrock, Bristol Myers Squibb/Celgene, Celgene, CTI BioPharma, Geron, GlaxoSmithKline, Imago Bioscience, iOMEDICO, Incyte, Janssen, Kartos, MPN Hub, MSD, Novartis, Pfizer, PharmaEssentia, Protagonist, Roche, Sierra Oncology. Patent issued for a bromodomain and extraterminal motif (BET) inhibitor and royalties received from RWTH Aachen University; PB: Received honoraria and/or research funding from AbbVie, Blueprint, BMS, Cogent, CTI BioPharma, Disc, Geron, GlaxoSmithKline, Incyte, Ionis, Janssen, Jubilant, Kartos, Karyopharm, Morphic, MorphoSys, Novartis, PharmaEssentia, Sumitomo, and Telios. ME: Received advisory board and speakers bureau membership, research funding and/or honoraria from Bristol Myers Squibb, Gad Medical, GlaxoSmithKline, and Novartis. VG: Received consulting fees, honoraria, Board of Directors or advisory board/committee membership and/or data Safety Monitoring Board participation from AbbVie, Bristol Myers Squibb/Celgene, Constellation Pharmaceuticals, CTI BioPharma, GlaxoSmithKline, Novartis, Pfizer, Sierra Oncology, SMP Oncology, Roche, Pfizer, and Sierra Oncology. Received travel support for European Hematology Association (EHA) 2023 (invited talk at a GlaxoSmithKline-sponsored myeloproliferative neoplasms education session). JJK: Received consulting fees and/or Board of Directors or advisory committee membership from AbbVie, AOP Health, AOP Orphan Pharmaceuticals, Bristol Myers Squibb, GlaxoSmithKline, Incyte, Novartis, and PharmaEssentia. JM: Received consulting fees, Board of Directors or advisory committee membership, research funding, honoraria and/or consulting or advisory committee participation from AbbVie, Bristol Myers Squibb/Celgene, Constellation Pharmaceuticals, CTI BioPharma, Galecto, Geron, GlaxoSmithKline, Imago Biosciences, Incyte, Janssen, Kartos Therapeutics, Karyopharm Therapeutics, Merck, MorphoSys, Novartis, Pfizer, PharmaEssentia, Prelude Therapeutics, Roche, and Sierra Oncology. VM: Received honoraria from GlaxoSmithKline. FP: Received consultancy, honoraria, and/or research funding from AbbVie, AOP Orphan Pharmaceuticals, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Karyopharm, Kyowa Kirin, MEI, Novartis, Roche, Sierra Oncology, and Sumitomo. CH: Received honoraria, research funding and/or speakers bureau membership from AbbVie, AOP, Bristol Myers Squibb, CTI BioPharma, Galecto, GlaxoSmithKline, MorphoSys, and Novartis.